LUND, Sweden, Jan. 30, 2019 /PRNewswire/ -- BioInvent International AB (OMXS: BINV) announces today that the U.S. Food and Drug Administration (FDA) has granted the Company orphan designation for its proprietary antibody BI-1206 for the treatment of mantle cell lymphoma (MCL). Orphan...
from PR Newswire: https://prn.to/2RWUFgU
No comments:
Post a Comment